ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

被引：0
|
作者：
Niesvizky, Ruben [1 ]
Richardson, Paul G. [2 ]
Gabrail, Nashat Y. [3 ]
Madan, Sumit [4 ]
Yee, Andrew J. [5 ]
Quayle, Steven N. [6 ]
Almeciga-Pinto, Ingrid [6 ]
Jones, Simon S. [6 ]
Houston, Lee [6 ]
Hayes, Denise [6 ]
Van Duzer, John [6 ]
Wheeler, Catherine [6 ]
Trede, Nikolaus S. [6 ]
Raje, Noopur S. [5 ]
机构：
[1] Weill Cornell Med Coll, Ctr Excellence Lymphoma & Myeloma, New York, NY USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancy,Dept Med Oncol,Jerome Lipp, Boston, MA 02115 USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Hematol Oncol, San Antonio, TX 78229 USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Acetylon Pharmaceut Inc, Boston, MA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 16 条
  • [1] ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (ACE-MM-200 STUDY)
    Niesvizky, R.
    Richardson, P.
    Gabrail, N.
    Madan, S.
    Yee, A.
    Shain, K.
    Hoffman, J.
    Pagel, J.
    Bensinger, W.
    Nooka, A.
    Agarwal, A.
    Matous, J.
    Raab, M. S.
    Terpos, E.
    Bhol, K.
    Tamang, D.
    Jones, S. S.
    van Duzer, J.
    Wheeler, C.
    Trede, N. S.
    Raje, N.
    HAEMATOLOGICA, 2016, 101 : 524 - 525
  • [2] Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells
    Quayle, Steven N.
    Almeciga-Pinto, Ingrid
    Tamang, David
    Yang, Min
    Jones, Simon S.
    CANCER RESEARCH, 2015, 75
  • [3] Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
    Niesvizky, Ruben
    Richardson, Paul G.
    Yee, Andrew J.
    Nooka, Ajay K.
    Raab, Marc S.
    Shain, Kenneth H.
    Gabrail, Nashat Y.
    Matous, Jeffrey
    Agarwal, Amit B.
    Hoffman, James
    Madan, Sumit
    Pagel, John M.
    San Miguel, Jesus
    Moreau, Philippe
    Mateos, Maria-Victoria
    Facon, Thierry
    Tamang, David
    Jones, Simon S.
    Markelewicz, Robert J., Jr.
    Wheeler, Catherine
    Trede, Nikolaus S.
    Raje, Noopur
    Terpos, Evangelos
    Bensinger, William I.
    BLOOD, 2016, 128 (22)
  • [4] ACY-1215, a selective inhibitor of HDAC6, synergizes with immunomodulatory drugs (IMiDs) to induce apoptosis of multiple myeloma (MM) cells
    Quayle, Steven N.
    Tamang, David
    Yang, Min
    Jones, Simon S.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)
    Quayle, Steven N.
    Jones, Simon S.
    BLOOD, 2013, 122 (21)
  • [6] Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM)
    Santo, Loredana
    Hideshima, Teru
    Kung, Andrew L.
    Jarpe, Matthew
    Cirstea, Diana
    Patel, Kishan
    Pozzi, Samantha
    Tseng, Jen C.
    Rodig, Scott J.
    Bradner, James
    Anderson, Kenneth C.
    Jones, Simon
    Raje, Noopur
    BLOOD, 2010, 116 (21) : 1235 - 1236
  • [7] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
    A Ray
    D S Das
    Y Song
    T Hideshima
    Y-T Tai
    D Chauhan
    K C Anderson
    Leukemia, 2018, 32 : 843 - 846
  • [8] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
    Ray, A.
    Das, D. S.
    Song, Y.
    Hideshima, T.
    Tai, Y-T
    Chauhan, D.
    Anderson, K. C.
    LEUKEMIA, 2018, 32 (03) : 843 - 846
  • [9] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)
    Raje, Noopur S.
    Bensinger, William
    Cole, Craig E.
    Lonial, Sagar
    Jagannath, Sundar
    Arce-Lara, Carlos E.
    Valent, Jason
    Rosko, Ashley E.
    Harb, Wael A.
    Sandhu, Irwindeep
    Bahlis, Nizar J.
    Reece, Donna
    Terpos, Evangelos
    Supko, Jeffrey
    Tamang, David
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J., Jr.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [10] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed -and Refractory Multiple Myeloma: Phase lb Results (ACE-MM-101 Study)
    Yee, Andrew J.
    Bensinger, William
    Voorhees, Peter M.
    Berdeja, Jesus G.
    Richardson, Paul G.
    Supko, Jeffrey
    Tamang, David
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J., Jr.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
12